Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.COWbVb-l.js ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...

"The last four or five games here, we’re in those games. So it’s not like there have been just horrible blowouts." ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.

So get your questions in now for Art and he will be with you between 4pm and 5pm GMT (11am to 12pm ET) to answer as many as he can ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report) and Roche ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...